e-learning
resources
Paris 2018
Tuesday, 18.09.2018
CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease
S. Sra (London, United Kingdom), K. Myall (London, United Kingdom), B. Lams (London, United Kingdom), S. Agarwal (London, United Kingdom), A. West (London, United Kingdom)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Session:
CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Session type:
Oral Presentation
Number:
3821
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Sra (London, United Kingdom), K. Myall (London, United Kingdom), B. Lams (London, United Kingdom), S. Agarwal (London, United Kingdom), A. West (London, United Kingdom). The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease. 3821
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004
Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002
Rituximab improves interstitial lung disease in rheumatoid arthritis patients
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021
Rheumatoid arthritis-associated lung disease
Source: Eur Respir Rev 2015; 24: 1-16
Year: 2015
Rheumatoid arthritis-associated interstitial lung disease: time trends
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021
Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016
Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1206-1208
Year: 2010
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis
Source: Eur Respir J 2004; 24 : 708
Year: 2004
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Rheumatoid arthritis-related lung disease
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020
Year: 2020
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Year: 2021
Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1322-1328
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept